Lung Cancer

Researchers traced the development of thousands of engineered human lung cancer cells within a mouse model of disease to examine metastasis.

The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.

Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.

The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.

AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.

The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.

The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.

For the three months ended Sept. 30, the Boulder, Colorado-based firm generated a revenue of $9.2 million, compared to $3.9 million year over year.

The investment bank sees the potential for strong revenue growth over time as Oncocyte expands its product portfolio and launches new tests.